The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
A simple "yes I'm scared to answer the question" would have been faster
Ricky
"Stt - you seem to have a grudge against certain posters (who probably cost you after you followed their recommendations)"
On the contrary, I haven't lost anything and I never followed anyone's recommendation. I traded some shares (trmr, rthm, byot), whilst continuing to post the warnings/red flags and rational bear case and sold based on my warnings and assertions and my own opinion.
All documented, see my posts. I sold trmr at 844p, high was around 870p, now around 200p (company now called nexn).
https://www.lse.co.uk/profiles/stt1/?page=30
Are YOUR investments dependent on what I think and nobody else?
Tell us what will the cash be at 31st March 2024 or the interims?
How much higher than £37m?
Fy2023 Ebitda & margins as well?
Readers can see for my posting history for themselves.
Read pages 70 to 80. Byot was being pumped, I posted the warnings and company/sector newsflow, the rampers more interested in the sp. The shares crashed and company confirmed was saying similar to my warnings.
https://www.lse.co.uk/profiles/stt1/?page=80
Scared of the question? You were claiming cash of around 29m last time around I think, when it was 37m. I didn't ask what you thought it would be, I asked what level you would consider "good"
Hallsworthy
Your post:
"Stt, with HVO results around the corner, what revenue and what profit level would you consider "good" with guidance at £56m, already ahead of market expectations"
Why not state what you, given you suggest to others they should ignore me? Is it because you know I've been right in the past on Byot, Trmr, rthm, etc etc...
What would you say the cash as of March 31st or interims will be? Declining or significantly ahead of the £37m?
What about for fy results:
Ebitda?
Margin?
Buy I mean
Another 2.7m but has gone through but what to they know ;)
Who gives a toss what he thinks?
....
Thanks Danny, cheers
Stt - you seem to have a grudge against certain posters (who probably cost you after you followed their recommendations) - you are wrong on Hvo though . The Company is growing revenue's by £6m + p.a (obviously this equates to a smaller % as they get bigger) - More importantly, profitability and cash generation is moving at a higher percentage (Revenue is vanity) - you stated on March 13th 'Despite all the talking up, no evidence of significant buying/holding by institutionS.' - which has since been shown to be completely wrong. You have been on about Hvo being a pump and dump ever since the 9p days and compared it unfavourably with Tly which were 30p+. This situation has completely reversed Hvo are very profitable and generating lots of cash whilst Tly is debt ridden and struggling to make a profit. When will you just give up on your rants?? (I know CF sold his share but we are now back above his sale level so whats the problem)
Starts around 25 minutes. There should be a timeline if you click …more
Stt, with HVO results around the corner, what revenue and what profit level would you consider "good" with guidance at £56m, already ahead of market expectations
How far in Danny ? Back to the 30’s and looking strong !
Ignore Birdbrain. HVIVO discussed on Vox Markets Fund Manager Series.
https://m.youtube.com/watch?v=Q2HhBz0Ua10&pp=ygULdm94IG1hcmtldHM%3D
There's a cancelled 50k trade gone through.
Look at all the small trades coming through.
Has been busy this morning
From today's Irish Independent:
Cathal Friel is progressing plans for a fifth stock market listing, announcing a formal intention to float his new European Green Transition (EGT) venture in London to develop a portfolio of green economy assets in Europe.
The venture has existing assets, including a rare earth minerals exploration licence in Sweden but will look to raise equity via a London listing on the AIM market to fund further merger and acquisition (M&A) activity to build up a portfolio.
Panmure Gordon is acting as Nominated Adviser, sole bookrunner and broker to the Company on its proposed Fundraise and Admission.
EGT also intends to launch a retail offering through the Bookbuild platform and a further announcement will be made in due course.
Cathal Friel has already delivered four stock market listings – Fastnet Oil and Gas in 2012, Amryt Pharma in 2016, Open Orphan (now hVivo) in 2019 and Poolbeg Pharma two years ago. The Dublin based businessman has developed a model of equity-funded expansion including organic growth and buying low-cost or distressed assets with paper rather than cash.
Amryt Pharma floated with a market cap of €29m and was sold last year for $1.48bn (€1.38bn).
The new venture, EGT, is developing a portfolio of green economy assets in Europe.
It will launch with a number of existing assets including the mineral licences in Sweden known as the Olserum Rare Earth Element (REE) project. REEs are a set of 17 metallic elements used in technology including electric vehicles and wind turbines. EGT says Olserum has the potential to be progressed to become Europe’s first commercial stage rare earth mine.
In addition EGT plans to follow what it says will be a disciplined M&A focused model and has already acquired an exciting portfolio of assets, notably their principal Olserum Rare Earth Element (REE) project.
Management has already identified a pipeline of additional green economy assets, some of which the Directors believe could be acquired for a fraction of the capital that has previously been invested in them.
Cathal Friel is heavily involved in the new venture as co-founder, largest shareholder and non executive director and the leadership team also includes CEO Aiden Lavelle, a Chartered Geologist with 16 years’ industry experience; and CFO Jack Kelly, a Chartered Accountant with extensive experience in M&A.
Commenting on the plans Cathal Friel said EGT will apply an our M&A focused approach of targeting distressed and undervalued assets towards prospects in the green economy.
"This approach has already generated success, delivering value across a range of public companies, namely Cove Energy plc, Amryt Pharma plc and hVIVO plc. We aim to repeat this formula with EGT.”
“We have chosen to list in London as we are very confident in its depth of capital and talent, and its unique understanding of green economy projects. London is a world leading capital market for small cap
Just focus on the many positives here and don’t rise to the pathetic bait. It will kill him.
“I see a questionable business model”
I see the biggest cretyn ever to have trolled on any BB ever!
The other point worth making.
The company will be paying for 2 leases for months. The current one and the new one at the new facility.
"The new facility's first phase is anticipated to reach completion in Q1 2024, with the full site expected to be operational by Q2 2024. hVIVO's current Whitechapel and Queen Mary Bioenterprises Centre (QMB) clinics will close in 2024 but will remain fully operational throughout this transition, ensuring uninterrupted service delivery to the Company's clients."
https://polaris.brighterir.com/public/hvivo/news/rns/story/xlkgv3w/export
How much is the new lease costing them?
Luckymaybe
"Please post the evidence"
Read the rns', company newsflow.
Read my posting history. Look at the warnings on Trmr/RTHM/Nano/Byot. Virtually everything came true and shares crashed.
Company newsflow:
There's no evidence of institutions buying in 2021, 2022, 2023.
Shares on loan avg around 10-11m during 2022-2023.
Feb 2022 - CEO appointed.
Feb 2023 - CEO receives >7m options, awarded to 1 director.
Talk of nominal dividend, institutions buying 1-2%, which is hardly anything for institutions.
Repeatedly tipped in media over past 3 months, same message repeated.
Shares rise on media tips.
After they were tipped in the media,
Feb 2024 Chairman dumps majority of his holding at 28p. He had been buying 2.5years earlier at around 26p and they reached profit since.
The company figures show growth has slowed significantly
Fy2022: £48.5m (+30%)
Fy2023: £56m (+15.5%)
Fy2024: £62m(+10.7%)
"Full year revenue of £56.0 million, an increase of 15.5% (2022: £48.5 million)
Revenue guidance of £62 million for 2024"
https://polaris.brighterir.com/public/hvivo/news/rns/story/xopzn1r/export
My posting history is consistent.
https://www.lse.co.uk/profiles/stt1/
I see a questionable business model
You think that’s bad. You should see what he has written over on ADVFN. Waffling on about penalties, timescales and Mike Lynch. He does seem to have a bee in his twat, sorry bonnet about slowed growth and the CEO dumping a majority of his shares doesn’t he.
Thanks for posting Kingy. Very encouraging to see our prospects so well presented by Mo Khan. I struggle to see any significant weakness in our business model.
Stt what kind of Muppet are you. What is your objective here. I am a holder here, however I agree with a little of what you say. But please back your points with evidence. You come across as a disgruntled fool. There are some issues here but I believe the prospects are on balance in our favour, thus I retain my investments here.